Bio-Gene Technology Ltd Capital Reinvestment Ratio

Latest as of June 2022: 0.16x

Bio-Gene Technology Ltd capital reinvestment ratio. Bio-Gene Technology Ltd (BGT) has a Capital Reinvestment Ratio of 0.16x as of June 2022, meaning it reinvests 0% of its operating cash flow (AU$43.52K) in capital expenditures (AU$6.84K). Check Bio-Gene Technology Ltd (BGT) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Capital Reinvestment Ratio

0.16x

Capex / Operating Cash Flow

Operating Cash Flow

AU$43.52K

AUD

Capital Expenditures

AU$6.84K

AUD

Data as of

Jun 2022

Most recent filing

Capital Reinvestment Ratio of Bio-Gene Technology Ltd (2022–2022)

Capital reinvestment ratio of Bio-Gene Technology Ltd from 2022 to 2022. This chart tracks Bio-Gene Technology Ltd's Capital Reinvestment Ratio across 1 annual periods. Also explore how fast is Bio-Gene Technology Ltd growing its equity to track the company's year-over-year net asset growth rate.

Bio-Gene Technology Ltd Capital Reinvestment Ratio by Year (2022–2022)

Bio-Gene Technology Ltd capital reinvestment ratio by year from 2022 to 2022. For the full cash flow conversion analysis, see Bio-Gene Technology Ltd (BGT) cash conversion ratio.

Year	Reinvestment Ratio	Operating CF (AUD)	Capital Expenditures	YoY Change
2022	0.16x	AU$43.52K	AU$6.84K	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow